Skip to content

Olivier Gryson

  • Home
  • Pharma Marketing in the Age of AI Search
  • Glossary
  • Contact
  • About
Olivier Gryson

Pharma Marketing in
the Age of AI Search

Pharma Marketing in the Age of AI Search is available at Amazon.com

A practical guide to winning visibility, trust, and relevance in a search- and AI-driven healthcare world

Pharma Marketing in the Age of AI Search is available at Amazon.
  • Caregiver Queries: The Overlooked Half of Patient-Side AI Search

    July 13, 2026

    Caregivers now drive a distinct, growing share of patient-side AI health search. Here’s why pharma GEO strategies overlook them — and how to fix it.

    Read more


  • How ChatGPT, Claude, and Google AI Overviews Select Sources in Pharma GEO

    July 5, 2026

    This article compares how ChatGPT, Claude, and AI overviews actually selects sources, and builds every recommendation around the rules that already govern pharma promotion.

    Read more


  • Global GEO vs Local AI Search in Pharma: Why Global Content Doesn’t Guarantee Local AI Citations

    July 3, 2026

    Global GEO makes a pharma brand citable — it doesn’t guarantee AI gets the local answer right. Here’s why, with the evidence.

    Read more


  • GEO for Rare Diseases: Unique Opportunities and Challenges

    June 29, 2026

    GEO for Rare Diseases: Unique Opportunities and Challenges For rare diseases, visibility is no longer only about ranking on Google — it is about becoming a trusted source that AI assistants cite. Why Is GEO Particularly Important for Rare Diseases? The Rarity Paradox Rare diseases are anything but rare at the population level. According to…

    Read more


  • How to Use AI to Write Pharma Content That AI Search Systems Are More Likely to Cite

    June 16, 2026

    Can you use AI to write pharma content that gets cited in AI search? Yes — with conditions. AI handles the structure; a qualified human must verify every clinical claim, every guideline, every mechanism of action against primary sources. That verification is what makes the content citable. From August 2026, EU AI Act Article 50…

    Read more


  • The AI-Informed Patient: Rethinking Pharma Messaging Before the HCP Visit

    June 7, 2026

    A growing share of patients now arrive at HCP appointments already briefed by AI. They’ve self-diagnosed, compared treatments, and formed opinions about your brand. For pharma, the competition for therapeutic trust now begins before the consultation room door opens.

    Read more


  • How to Build an Unbranded Disease Education Page That Ranks in AI Search

    May 30, 2026

    AI systems favour content that is factual, neutral, and expertly attributed. That description fits unbranded disease education perfectly — and branded pharma content almost never. This guide gives pharma teams a complete, compliant build process for disease education pages that get cited in AI-generated answers.

    Read more


  • Pharma GEO: Building Knowledge Graphs That AI Systems Trust

    May 25, 2026

    Pharma GEO: Building Knowledge Graphs That AI Systems Trust What Is Generative Engine Optimization (GEO) — and Why Does Pharma Need It Now? Generative Engine Optimization (GEO) is the practice of structuring digital content so that large language models (LLMs) — ChatGPT, Perplexity AI, Google Gemini, Microsoft Copilot — can find, understand, and cite it when…

    Read more


  • Digital Transformation in Pharma: How GEO Is Reshaping the Entire Organization

    May 6, 2026

    How GEO and AI search will transform marketing, medical affairs, MLR, regulatory, legal, and IT in pharma — and what each function must do now.

    Read more


1 2 3
Next Page

Published on: December 28, 2025
Last updated: July 3, 2026

© 2026 Olivier Gryson - Terms of Use and Privacy - Contact

Content on this website is provided for informational and thought-leadership purposes only. All examples, scenarios, and recommendations are illustrative and intended to stimulate discussion, not to provide medical, legal, regulatory, or compliance advice.

Any pharmaceutical activities must be conducted in accordance with applicable laws and regulations, relevant industry codes of practice (including those of EFPIA and IFPMA), and internal Medical, Legal, and Regulatory (MLR) review and approval processes. Responsibility for compliance remains with the reader and their organization.

  • Home
  • Pharma Marketing in the Age of AI Search
  • Glossary
  • Contact
  • About